Amyloid and tau cerebrospinal fluid biomarkers in HIV infection

BMC Neurology

Volumn 9, Issue , 2009, Pages

  Gisslén, Magnus ^a   Krut, Jan ^a   Andreasson, Ulf ^a   Blennow, Kaj ^a   Cinque, Paola ^b   Brew, Bruce J ^c   Spudich, Serena ^d   Hagberg, Lars ^a   Rosengren, Lars ^a   Price, Richard W ^d   Zetterberg, Henrik ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; AMYLOID PROTEIN; TAU PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN INJURY; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSTIMULATION; MALE; NERVE CELL LESION; NEUROLOGIC DISEASE; OPPORTUNISTIC INFECTION; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; SYMPTOM; AIDS RELATED COMPLEX; ANALYSIS OF VARIANCE; BLOOD; CEREBROSPINAL FLUID; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; GENETICS; HIV ASSOCIATED DEMENTIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; MULTICENTER STUDY; PRINCIPAL COMPONENT ANALYSIS;

ADULT; AGED; AIDS DEMENTIA COMPLEX; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PRINCIPAL COMPONENT ANALYSIS; TAU PROTEINS;

EID: 74549114139     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-9-63     Document Type: Article

References (59)

1. Brew BJ, Pemberton L, Cunningham P, Law MG. Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis 1997, 175(4):963-966. 10.1086/514001, 9086160.
2. Ellis RJ, Hsia K, Spector SA, Nelson JA, Heaton RK, Wallace MR, Abramson I, Atkinson JH, Grant I, McCutchan JA. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol 1997, 42(5):679-688. 10.1002/ana.410420503, 9392566.
3. Gisslen M, Fuchs D, Svennerholm B, Hagberg L. Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr 1999, 21(4):271-276.
4. Spudich SS, Nilsson AC, Lollo ND, Liegler TJ, Petropoulos CJ, Deeks SG, Paxinos EE, Price RW. Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis 2005, 5:98. 10.1186/1471-2334-5-98, 1299327, 16266436.
5. Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis 1988, 158(5):1079-1083.
6. Brew BJ, Rosenblum M, Cronin K, Price RW. AIDS dementia complex and HIV-1 brain infection: clinical-virological correlations. Ann Neurol 1995, 38(4):563-570. 10.1002/ana.410380404, 7574452.
7. d'Arminio Monforte A, Cinque P, Mocroft A, Goebel FD, Antunes F, Katlama C, Justesen US, Vella S, Kirk O, Lundgren J. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 2004, 55(3):320-328. 10.1002/ana.10827, 14991809.
8. Gisslen M, Svennerholm B, Norkrans G, Franzen C, Sall C, Svensson R, Oberg S, Hagberg L. Cerebrospinal fluid and plasma viral load in HIV-1-infected patients with various anti-retroviral treatment regimens. Scand J Infect Dis 2000, 32(4):365-369. 10.1080/003655400750044926, 10959643.
9. Mellgren A, Antinori A, Cinque P, Price RW, Eggers C, Hagberg L, Gisslen M. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment. Antivir Ther 2005, 10(6):701-707.
10. Spudich S, Lollo N, Liegler T, Deeks SG, Price RW. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis 2006, 194(12):1686-1696. 10.1086/508750, 17109340.
11. Price RW, Spudich S. Antiretroviral therapy and central nervous system HIV type 1 infection. J Infect Dis 2008, 197(Suppl 3):S294-306. 10.1086/533419, 2628635, 18447615.
12. Sinclair E, Ronquillo R, Lollo N, Deeks SG, Hunt P, Yiannoutsos CT, Spudich S, Price RW. Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr 2008, 47(5):544-552. 10.1097/QAI.0b013e318162754f, 18362693.
13. Valcour VG, Shikuma CM, Watters MR, Sacktor NC. Cognitive impairment in older HIV-1-seropositive individuals: prevalence and potential mechanisms. AIDS 2004, 18(Suppl 1):S79-86. 1388077, 15075502.
14. Alisky JM. The coming problem of HIV-associated Alzheimer's disease. Med Hypotheses 2007, 69(5):1140-1143. 10.1016/j.mehy.2007.02.030, 17433562.
15. Pulliam L. HIV regulation of amyloid beta production. J Neuroimmune Pharmacol 2009, 4(2):213-217. 10.1007/s11481-009-9151-9, 19288202.
16. Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE. Accelerated Tau deposition in the brains of individuals infected with human immunodeficiency virus-1 before and after the advent of highly active anti-retroviral therapy. Acta Neuropathol 2006, 111(6):529-538. 10.1007/s00401-006-0037-0, 16718349.
17. Gelman BB, Schuenke K. Brain aging in acquired immunodeficiency syndrome: increased ubiquitin-protein conjugate is correlated with decreased synaptic protein but not amyloid plaque accumulation. J Neurovirol 2004, 10(2):98-108. 10.1080/13550280490279816, 15204928.
18. Esiri MM, Biddolph SC, Morris CS. Prevalence of Alzheimer plaques in AIDS. J Neurol Neurosurg Psychiatry 1998, 65(1):29-33. 10.1136/jnnp.65.1.29, 2170157, 9667557.
19. Green DA, Masliah E, Vinters HV, Beizai P, Moore DJ, Achim CL. Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. Aids 2005, 19(4):407-411. 10.1097/01.aids.0000161770.06158.5c, 15750394.
20. Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, Blennow K. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 2007, 23(5):316-320. 10.1159/000100926, 17374949.
21. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009, 65(4):403-413. 10.1002/ana.21610, 2696350, 19296504.
22. Brew BJ, Pemberton L, Blennow K, Wallin A, Hagberg L. CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology 2005, 65(9):1490-1492. 10.1212/01.wnl.0000183293.95787.b7, 16275845.
23. Andersson L, Blennow K, Fuchs D, Svennerholm B, Gisslen M. Increased cerebrospinal fluid protein tau concentration in neuro-AIDS. J Neurol Sci 1999, 171(2):92-96. 10.1016/S0022-510X(99)00253-1, 10581374.
24. Ellis RJ, Seubert P, Motter R, Galasko D, Deutsch R, Heaton RK, Heyes MP, McCutchan JA, Atkinson JH, Grant I. Cerebrospinal fluid tau protein is not elevated in HIV-associated neurologic disease in humans. HIV Neurobehavioral Research Center Group (HNRC). Neurosci Lett 1998, 254(1):1-4. 10.1016/S0304-3940(98)00549-7, 9780077.
25. Green AJ, Giovannoni G, Hall-Craggs MA, Thompson EJ, Miller RF. Cerebrospinal fluid tau concentrations in HIV infected patients with suspected neurological disease. Sex Transm Infect 2000, 76(6):443-446. 10.1136/sti.76.6.443, 1744244, 11221126.
26. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992, 41(RR-17):1-19.
27. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology 1991, 41(6):778-785.
28. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007, 69(18):1789-99. 10.1212/01.WNL.0000287431.88658.8b, 17914061.
29. Cinque P, Cleator GM, Weber T, Monteyne P, Sindic C, Gerna G, van Loon AM, Klapper PE. Diagnosis and clinical management of neurological disorders caused by cytomegalovirus in AIDS patients. European Union Concerted Action on Virus Meningitis and Encephalitis. J Neurovirol 1998, 4(1):120-132. 10.3109/13550289809113490, 9531020.
30. Weber T, Klapper PE, Cleator GM, Bodemer M, Luke W, Knowles W, Cinque P, Van Loon AM, Grandien M, Hammarin AL, et al. Polymerase chain reaction for detection of JC virus DNA in cerebrospinal fluid: a quality control study. European Union Concerted Action on Viral Meningitis and Encephalitis. J Virol Methods 1997, 69(1-2):231-237. 10.1016/S0166-0934(97)00152-3, 9504768.
31. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34(7):939-944.
32. Vanderstichele H, Blennow K, D'Heuvaert N, Buyse M, Wallin A, Andreasen N, Seubert P, Voorde A, Vanmechelen E. Development of a specific diagnostic test for measurement of amyloid(1-42) beta in CSF. Progress in Alzheimer's and Parkinson's Diseases 1998, 773-778. New York: Plenum Press, Fisher A, Hanin I, Yoshida M.
33. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?. Mol Chem Neuropathol 1995, 26(3):231-245. 10.1007/BF02815140, 8748926.
34. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Perre B, Sjogren M, Andreasen N, Blennow K. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000, 285(1):49-52. 10.1016/S0304-3940(00)01036-3, 10788705.
35. Eriksson L, Johansson E, Kettaneh-Wold N, Trygg J, Wikström C, Wold S. Multi- and Megavariate Data Analysis Part I: Basic Principles and Applications. Second revised and enlarged edition 2006, Umea, Sweden: UMETRICS.
36. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, Flier WM, Blankenstein MA, Ewers M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009, 302(4):385-393. 10.1001/jama.2009.1064, 19622817.
37. Price RW, Epstein LG, Becker JT, Cinque P, Gisslen M, Pulliam L, McArthur JC. Biomarkers of HIV-1 CNS infection and injury. Neurology 2007, 69(18):1781-1788. 10.1212/01.wnl.0000278457.55877.eb, 17967994.
38. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006, 368(9533):387-403. 10.1016/S0140-6736(06)69113-7, 16876668.
39. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 2004, 1(2):213-225. 10.1602/neurorx.1.2.213, 534929, 15717022.
40. Gisslen M, Hagberg L, Rosengren L, Brew BJ, Cinque P, Spudich S, Price RW. Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers. J Neuroimmune Pharmacol 2007, 2(1):112-119. 10.1007/s11481-006-9035-1, 18040834.
41. Andreasson U, Portelius E, Andersson M, Blennow K, Zetterberg H. Aspects of beta-amyloid as a biomarker for Alzheimer's disease. Biomarkers Med 2007, 1(1):59-78.
42. Olsson A, Hoglund K, Sjogren M, Andreasen N, Minthon L, Lannfelt L, Buerger K, Moller HJ, Hampel H, Davidsson P, et al. Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp Neurol 2003, 183(1):74-80. 10.1016/S0014-4886(03)00027-X, 12957490.
43. Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, Buchhave P, Londos E, Umek RM, Minthon L, et al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol 2008, 65(8):1102-1107. 10.1001/archneur.65.8.1102, 18695061.
44. Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, Burger K, Hampel H, Frolich L, Wolf S, et al. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry 2008,
45. Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003, 60(4):652-656.
46. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006, 59(3):512-519. 10.1002/ana.20730, 16372280.
47. Nebuloni M, Pellegrinelli A, Ferri A, Bonetto S, Boldorini R, Vago L, Grassi MP, Costanzi G. Beta amyloid precursor protein and patterns of HIV p24 immunohistochemistry in different brain areas of AIDS patients. Aids 2001, 15(5):571-575. 10.1097/00002030-200103300-00005, 11316993.
48. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41(4):479-486.
49. Rempel HC, Pulliam L. HIV-1 Tat inhibits neprilysin and elevates amyloid beta. AIDS 2005, 19(2):127-135. 10.1097/00002030-200501280-00004, 15668537.
50. Achim CL, Adame A, Dumaop W, Everall IP, Masliah E. Increased accumulation of intraneuronal amyloid beta in HIV-infected patients. J Neuroimmune Pharmacol 2009, 4(2):190-199. 10.1007/s11481-009-9152-8, 19288297.
51. Mankowski JL, Queen SE, Tarwater PM, Fox KJ, Perry VH. Accumulation of beta-amyloid precursor protein in axons correlates with CNS expression of SIV gp41. J Neuropathol Exp Neurol 2002, 61(1):85-90.
52. Sjogren M, Gisslen M, Vanmechelen E, Blennow K. Low cerebrospinal fluid beta-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment. Neurosci Lett 2001, 314(1-2):33-36. 10.1016/S0304-3940(01)02285-6, 11698140.
53. Mattsson N, Axelsson M, Haghighi S, Malmestrom C, Wu G, Anckarsater R, Sankaranarayanan S, Andreasson U, Fredrikson S, Gundersen A, et al. Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis. Mult Scler 2009, 15(4):448-454. 10.1177/1352458508100031, 19153172.
54. Navia BA, Cho ES, Petito CK, Price RW. The AIDS dementia complex: II. Neuropathology. Ann Neurol 1986, 19(6):525-535. 10.1002/ana.410190603, 3014994.
55. Trojanowski JQ, Schuck T, Schmidt ML, Lee VM. Distribution of tau proteins in the normal human central and peripheral nervous system. J Histochem Cytochem 1989, 37(2):209-215.
56. Braak H, Braak E. Diagnostic criteria for neuropathologic assessment of Alzheimer's disease. Neurobiol Aging 1997, 18(4 Suppl):S85-88. 10.1016/S0197-4580(97)00062-6, 9330992.
57. Stanley LC, Mrak RE, Woody RC, Perrot LJ, Zhang S, Marshak DR, Nelson SJ, Griffin WS. Glial cytokines as neuropathogenic factors in HIV infection: pathogenic similarities to Alzheimer's disease. J Neuropathol Exp Neurol 1994, 53(3):231-238. 10.1097/00005072-199405000-00003, 8176406.
58. Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE. Influence of HAART on HIV-related CNS disease and neuroinflammation. J Neuropathol Exp Neurol 2005, 64(6):529-536.
59. Navia BA, Jordan BD, Price RW. The AIDS dementia complex: I. Clinical features. Ann Neurol 1986, 19(6):517-524. 10.1002/ana.410190602, 3729308.